NRXP U.S.: Nasdaq

    NRX Pharmaceuticals Inc.

    After Hours
    Last Updated: Sep 24, 2021 7:59 p.m. EDT Delayed quote

    $ 9.45

    0.03 0.32%
    After Hours Volume: 25.11K
    Close Chg Chg %
    $9.42 -0.59 -5.89%
    Advanced Charting
    Volume: 1.03M 65 Day Avg: 4.91M
    21% vs Avg
    9.33 Day Range 10.08
    8.39 52 Week Range 76.99

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    NRXP Overview


    5 Day
    • -11.96%
    1 Month
    • -32.71%
    3 Month
    • -32.95%
    • -61.39%
    1 Year
    • -12.21%

    IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals

    on Zacks.com

    Why NRx Pharmaceuticals Stock Vaulted Higher Today

    on Motley Fool

    Why NRx Pharmaceuticals Stock Is Sinking Today

    on Motley Fool

    Why NRx Pharmaceuticals Stock Jumped 11.8% Today

    on Motley Fool

    Could This Be the Biggest News in Treating Severe COVID So Far?

    on Motley Fool

    Here's Why NRx Pharmaceuticals Stock Dropped Monday

    on Motley Fool

    Why NRx Pharmaceuticals Stock Is Soaring Today

    on Motley Fool

    NRx Trial Proves Aviptadil Helps Prevent “Cytokine Storm”; Shares Spike 45%

    on TipRanks.com

    Why NRx Pharmaceuticals Stock Is Skyrocketing Today

    on Motley Fool

    NRX Pharmaceuticals Inc.

    NRX Pharmaceuticals, Inc. is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure (the "NRx COVID-19 Drug"). It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior the "NRx Antidepressant Drug Regimen." The company is headquartered in Wilmington, DE.